Vericel shows solid revenue growth, high gross margins, and positive free cash flow, but this is paired with modest profitability and a very elevated valuation multiple. Recent price action reflects short-term momentum with a high-volume advance and improving daily MACD against a backdrop of negative 12‑month returns and price trading below the 50‑day moving average. Short interest metrics indicate meaningful bearish positioning and a high short-volume ratio, even as recent news flow has been predominantly positive around revenue growth and margins.